Wireva

Spanish biochemist Margarita Salas's phi29 enzyme yields CSIC's most profitable patent

Margarita Salas, the Spanish biochemist who spent decades studying a bacteriophage, helped develop a DNA polymerase enzyme that became the Spanish National Research Council's most profitable patent and is now used in laboratories worldwide.

Spanish biochemist Margarita Salas built a career around a virus that infects bacteria, and the research produced one of the most profitable patents in the history of Spain's National Research Council, the CSIC. In June 2019, in Vienna, she received the European Inventor Award, presented by the European Patent Office in the lifetime achievement category, and she also won the public vote prize. Her message on that occasion was that high-quality basic research can produce applications that are not foreseeable at first sight, and that those applications can be profitable.

Salas earned her doctorate in biochemistry in 1963 at the Complutense University of Madrid. She then spent three years at New York University working with Severo Ochoa, the Nobel laureate. In 1967 she returned to Spain and founded the country's first molecular genetics research group at the CSIC. From that point on, she worked with the bacteriophage phi29, often in collaboration with her husband, the scientist Eladio Viñuela.

The research led to a discovery. While studying the way the phage infects its host bacterium, the team observed that the infection triggers the synthesis of a DNA polymerase with remarkable properties for amplifying DNA. According to the CSIC, Luis Blanco and Margarita Salas discovered this enzyme in 1984. A DNA polymerase is the enzyme that synthesizes DNA, and the phi29 version can multiply a DNA sample in a simple, fast and reliable way.

That capability has made the enzyme useful across several fields. Salas herself gave an example: when scientists hold only tiny amounts of genetic material, such as a single hair found at a crime scene or fragments from an archaeological site, the enzyme can amplify the DNA millions of times so that it can be analysed, sequenced and studied. The CSIC says the enzyme is used in forensic medicine, oncology and archaeology, among other areas, and it is included in DNA amplification kits sold to molecular biology laboratories.

The first patent covering applications of the enzyme was in force from 1989 to 2009. Its inventors were three CSIC research professors: Luis Blanco, Antonio Bernad and Margarita Salas. According to data from the CSIC's Deputy Vice-Presidency for Knowledge Transfer, it is the most profitable patent the organisation has filed. Between 2003 and 2009 it accounted for more than half of the institution's copyright income. The CSIC states that the money was returned to research funded by public money.

The patent expired in 2009, but the team continued improving the technology. Those improvements were patented and exploited by several companies, according to a 2019 CSIC statement. The Spanish Patent and Trademark Office lists her patents, nearly all of them filed by the CSIC.

In Vienna, Salas summed up her view in a line the CSIC used as a headline: without basic research there is no development. She said the award recognised the basic research she had carried out throughout her life, and that it had produced a biotechnological application that was very important and very profitable for the CSIC, for the inventors and for their centre.

Salas died in Madrid on 7 November 2019, at the age of 80. The CSIC noted at the time that she had still been working in her laboratory at the Severo Ochoa Molecular Biology Centre, and it recalled another of her remarks from Vienna: I cannot conceive of life without research.

The enzyme remained relevant after her death. In April 2020, the CSIC and the National Centre for Cancer Research, CNIO, announced a project to detect the coronavirus using an improved version of the enzyme. The aim, according to the CSIC, was to make a diagnosis in under an hour without specialised equipment. Unlike PCR, the enzyme's mechanism works even at room temperature, and the researchers hoped to develop a portable device resembling a pregnancy test, with first results expected by autumn 2020.

Salas was also recognised with honours during her lifetime. The Spanish Patent and Trademark Office notes that she was the first woman to receive the Echegaray Medal in 2016, and she had been a member of the Royal Spanish Academy since 2003. Since December 2019, the CSIC's Centre for Biological Research has carried her name.